Trial Profile

A Safety and Feasibility Trial of Boost Vaccinations of a Lethally Irradiated, Allogeneic Pancreatic Tumor Cell Vaccine Transfected With the GM-CSF Gene Given Alone or in Combination With Either a Single Intravenous Dose or Daily Metronomic Oral Doses of Cyclophosphamide for the Treatment of Surgically Resected Pancreatic Adenocarcinoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 10 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cyclophosphamide (Primary) ; Cyclophosphamide (Primary) ; Tumour cell vaccine-GVAX (Primary)
Indications Adenocarcinoma; Head and neck cancer; Pancreatic cancer
Focus Adverse reactions

03 Jul 2025 Arms increased from 5 to 7. Efficacy related primary endpoint replaced with safety endpoints. Trial focus changed from efficacy to safety.
06 Aug 2024 Planned End Date changed from 1 Aug 2024 to 1 Jul 2025.
30 Oct 2023 Planned End Date changed from 1 Aug 2023 to 1 Aug 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com